House Lawmakers Eye Volume, Other Criteria In Defining Drug Compounding
A bipartisan group of lawmakers is mulling how to employ volume restrictions – potentially in addition to other limitations such as percentage of business or providing patient prescriptions within a certain period – in drawing a line between drug compounding and manufacturing in draft legislation. FDA, however, expressed concern about how these standards would be defined, possibly creating a loophole or a complicated regulatory scheme.
quoted from here